NHS cancer patients missing out on innovative drugs Review of availability of drugs for breast and prostate cancer concludes UK approach is not fit for purpose
Thousands of NHS cancer patients in the UK are missing out on innovative treatments available in countries of comparable wealth partly because of a failure by medicines regulators to negotiate with the pharmaceutical industry on the price of drugs, charities have said.
Breast Cancer Now and Prostate Cancer UK have reviewed different drug systems and the availability of drugs for breast and prostate cancer and concluded that the UK approach is not fit for purpose. Continue reading... The Guardian
See also:
Thousands of NHS cancer patients in the UK are missing out on innovative treatments available in countries of comparable wealth partly because of a failure by medicines regulators to negotiate with the pharmaceutical industry on the price of drugs, charities have said.
Breast Cancer Now and Prostate Cancer UK have reviewed different drug systems and the availability of drugs for breast and prostate cancer and concluded that the UK approach is not fit for purpose. Continue reading... The Guardian
See also:
- International comparisons of Health TechnologyAssessment Breast Cancer Now and Prostate Cancer UK
- Thousands of NHS patients missing out on cancer treatments available in other countries – as UK appraisal systems lack power to negotiate drug prices Breast Cancer Now
No comments:
Post a Comment